Drug Trial Radar · NCT00996983
Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer
Last checked: Nov 20, 2026Latest source record: Mar 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
16
Planned (sponsor's estimate)
Start
Sep 2009
Primary completion
Dec 2024
Study completion Dec 2024
Sponsor
- Lead sponsor
- National Cancer Institute, NaplesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neuropathic pain is difficult to control because it is only partially sensitive to opioid analgesics, and requires the addition of other therapies such as antidepressants and epileptics. Ziconotide is a drug that is used to treat neuropathic pain in patients who have had inadequate pain control with prior combination of medicines.
Conditions
- Pain
- Neuropathic Pain
- Intractable Pain
- Cancer
Interventions
ziconotideDrug
intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response rate (> 30% reduction in VASPI)Time frame: 48 hours after completion of titration phase
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Istituto Nazionale dei Tumori , Unita Terapia Antalgica
Naples, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.